Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy

• Published in: Cancer cell international 2023-11, Vol.23 (1), p.1-281, Article 281
• Main Authors: Li, Yang, Liu, Yang, Yang, Keyan, Jin, Ling, Yang, Jing, Huang, Shuang, Liu, Ying, Hu, Bo, Liu, Rong, Liu, Wei, Liu, Ansheng, Zheng, Qinlong, Zhang, Yonghong
• Format: Article
• Language: English
• Subjects: B-cell lymphoma; CAR-T cell therapies; Cell cycle; Cell survival; Cell therapy; Chemotherapy; Children; Chimeric antigen receptors; Gene mutations; Lymphocytes; Lymphocytes B; Lymphocytes T; Lymphoma; Medical prognosis; Mutation; Next-generation sequencing; Non-Hodgkin's lymphoma; p53 Protein; Patients; Pediatric B-cell non-hodgkin Lymphomas; Pediatrics; Remission (Medicine); Survival analysis; Tumors
• ISSN: 1475-2867; 1475-2867
• DOI: 10.1186/s12935-023-03122-2

BackgroundChimeric antigen receptor (CAR)-T cell therapy has been used to treat pediatric refractory or relapsed mature B-cell non-Hodgkin lymphoma (r/r MB-NHL) with significantly improved outcomes, but a proportion of patients display no response or experience relapse after treatment. To investigate whether tumor-intrinsic somatic genetic alterations have an impact on CAR-T cell treatment, the genetic features and treatment outcomes of 89 children with MB-NHL were analyzed.Methods89 pediatric patients treated at multiple clinical centers of the China Net Childhood Lymphoma (CNCL) were included in this study. Targeted next-generation sequencing for a panel of lymphoma-related genes was performed on tumor samples. Survival rates and relapse by genetic features and clinical factors were analyzed. Survival curves were calculated using a log-rank (Mantel-Cox) test. The Wilcox sum-rank test and Fisher’s exact test were applied to test for group differences.ResultsA total of 89 driver genes with somatic mutations were identified. The most frequently mutated genes were TP53 (66%), ID3 (55%), and ARID1A (31%). The incidence of ARID1A mutation and co-mutation of TP53 and ARID1A was high in patients with r/r MB-NHL (P = 0.006; P = 0.018, respectively). CAR-T cell treatment significantly improved survival in r/r MB-NHL patients (P = 0.00081), but patients with ARID1A or ARID1A and TP53 co-mutation had poor survival compared to those without such mutations.ConclusionThese results indicate that children with MB-NHL harboring ARID1A or TP53 and ARID1A co-mutation are insensitive to initial conventional chemotherapy and subsequent CAR-T cell treatment. Examination of ARID1A and TP53 mutation status at baseline might have prognostic value, and risk-adapted or more effective therapies should be considered for patients with these high-risk genetic alterations.